Abbott's Exact Sciences buy, Blackstone and TPG's Hologic acquisition, and Water's BD transaction could herald a busy 2026 ...

The false negative rates do not appear out of line with the test's sensitivity figures, but issues have been raised with its workflow and the firm's marketing strategy.

Last week, readers were most interested in a story about the reasons behind the rapid adoption of BioMérieux's SpotFire syndromic qPCR instrument.

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

The digital revolution is now more quickly transforming pathology lab workflows, pointing towards accelerating adoption in the coming years.

Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.

The deal covers Myriad tests used for hereditary cancer risk assessment, as well as for ovarian and prostate cancer treatment.

The new financial agreements include $5 million of new term-loan proceeds to strengthen liquidity and funding for continued investment in product development.

During the year, the industry saw continued consolidation, the end of a key advisory body, the rise in DTC testing and advanced diagnostics, and another stab at PAMA reform.